DexCom Inc. closed 52.01% short of its 52-week high of $141.99, which the company achieved on April 9th.

Sands Capital, an investment management company, released its “Sands Capital Select Growth Fund” Q4 2024 investor letter. A ...

DexCom DXCM recently signed a licensing and data partnership with a privately held healthcare-at-home digital diagnostics company — Nanowear. Per the terms of the agreement, Nanowear will use glucose ...

The general mood among these heavyweight investors is divided, with 12% leaning bullish and 50% bearish. Among these notable ...

DexCom (NasdaqGS:DXCM) witnessed a 4% increase in its share price over the past week, as the company announced a significant integration of its G7 Continuous Glucose Monitoring Systems with Nanowear's ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of $98.00. The ...

DexCom Inc. closed 48.20% below its 52-week high of $142.00, which the company reached on March 26th.

$DXCM insiders have traded $DXCM stock on the open market 20 times in the past 6 months. Of those trades, 0 have been purchases and 20 have been sales. We have seen ...

DexCom (DXCM) announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for ...

DexCom DXCM recently signed a licensing and data partnership with a privately held healthcare-at-home digital diagnostics company — Nanowear. Per the terms of the agreement, Nanowear will use ...